Can a smartphone breathing game help Alpha-1 patients breathe easier?
NCT ID NCT07242079
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a simple, home-based breathing technique called the Active Cycle of Breathing Technique (ACBT) with augmented reality support in 50 adults with Alpha-1 antitrypsin deficiency. Participants did the breathing exercises twice daily and walked at least 5000 steps per day for six weeks. The goal was to see if using augmented reality helps patients stick with the program and feel more satisfied, while also tracking changes in breathlessness, lung function, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Active Cycle of Breathing Technique (ACBT) with augmented reality support
- What this could lead to
- If successful, this approach could offer a simple, home-based way to improve breathing, exercise capacity, and quality of life for people with Alpha-1 antitrypsin deficiency.
- What could go wrong
- This is a small, observational study with only 50 participants, so results may not apply to everyone. The main goal is to measure satisfaction and adherence, not to prove the technique works better than standard rehab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Parma
Parma, Italy, 43126, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to uncover hidden clues in rare liver disease
- RNA editing drug WVE-006 enters first human safety trial
- Gene-Editing shot aims to fix rare lung and liver disease
- Hidden gene behind breathlessness? study tests link to rare lung condition
- New drug YOLT-202 tested in early trial for rare lung and liver disease